Kode Biotech
Auckland, New Zealand· Est.
A New Zealand biotech leveraging protein‑engineering and RNA‑modulation to create pre‑clinical oncology and rare‑disease therapeutics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A New Zealand biotech leveraging protein‑engineering and RNA‑modulation to create pre‑clinical oncology and rare‑disease therapeutics.
Opportunities
Advancing pre‑clinical candidates into IND‑enabling studies and forming strategic alliances with larger pharma could unlock significant value.
Risk Factors
Technical translation risk, limited funding, and competition from established biotech firms pose major challenges.
Competitive Landscape
Competitors include global biotech firms developing bispecific antibodies and ASO therapeutics; Kode Biotech aims to differentiate through its integrated protein‑RNA platform.